{"id":2351,"date":"2021-06-14T10:37:41","date_gmt":"2021-06-14T09:37:41","guid":{"rendered":"https:\/\/touchimmunology.com\/?post_type=media_gallery&p=2351"},"modified":"2023-03-07T12:00:10","modified_gmt":"2023-03-07T12:00:10","slug":"john-e-harris-aad-vmx-2021-efficacy-and-safety-of-ruxolitinib-in-vitiligo","status":"publish","type":"media_gallery","link":"https:\/\/touchimmunology.com\/vitiligo\/conference-hub\/john-e-harris-aad-vmx-2021-efficacy-and-safety-of-ruxolitinib-in-vitiligo\/","title":{"rendered":"John E Harris, Dermatology Meeting News 2021: Efficacy and Safety of Ruxolitinib in Vitiligo"},"content":{"rendered":"

We caught up with Prof. John E Harris<\/strong> (University of Massachusetts Medical School, MA, USA) to discuss the safety and efficacy results from a Phase 2 study (NCT03099304) investigating ruxolitinib cream, a JAK1\/ JAK2 inhibitor, in adults with vitiligo.<\/p>\n

His abstract entitled ‘Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data From a Phase 2 Study<\/em>‘ was presented at the AAD VMX, 23-25 April 2021.<\/p>\n

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD.\u00a0<\/em><\/p>\n

Questions <\/strong><\/p>\n

    \n
  1. What is the rationale for the use of ruxolitinib cream in the treatment of adults with vitiligo? (0:05)<\/li>\n
  2. What was the design of the Phase 2 study, and what did the primary data analysis teach us? (1:19)<\/li>\n
  3. How did the 104-week data compare to that at 52 weeks in terms of the efficacy endpoints? (2:02)<\/li>\n
  4. What was the safety profile of treatment with ruxolitinib cream over 104 weeks? (2:40)<\/li>\n
  5. What is the clinical significance of these findings? (3:32)<\/li>\n<\/ol>\n

    Disclosures:<\/strong> Prof. John E Harris has acted and a consultant and investigator for Pfizer, Genzyme\/ Sanofi, Incyte, Rheos Medicines, Sun Pharmaceutical, LEO Pharma, Villaris Therapeutics, Dermavant and TeVido BioDevices; a consultant for AbbVie, Janssen, Almirall, Methuselah Health, Pandion, AnaptysBio, Avita, NIRA Biosciences, Admirx, Granular Therapeutics and Platelet BioGenesis; has Equity in TeVido Biodevices, Rheos, Villaris Therapeutics, NIRA Biosciences and is Founder of Villaris Therapeutics and NIRA Biosciences.<\/p>\n

    Support<\/strong>: Interview and filming supported by Touch Medical Media. Interview conducted by Gina Furnival.<\/p>\n

    Filmed in coverage of the AAD VMX 2021.<\/strong><\/p>\n

     <\/p>\n","protected":false},"excerpt":{"rendered":"

    We caught up with Prof. John E Harris (University of Massachusetts Medical School, MA, USA) to discuss the safety and efficacy results from a Phase 2 study (NCT03099304) investigating ruxolitinib cream, a JAK1\/ JAK2 inhibitor, in adults with vitiligo. His abstract entitled ‘Safety and Efficacy of Ruxolitinib Cream for the Treatment of Vitiligo: 104-Week Data […]<\/p>\n","protected":false},"featured_media":2352,"template":"","class_list":["post-2351","media_gallery","type-media_gallery","status-publish","has-post-thumbnail","hentry","vocabulary_1-vitiligo"],"acf":[],"_links":{"self":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2351","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery"}],"about":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/types\/media_gallery"}],"version-history":[{"count":6,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2351\/revisions"}],"predecessor-version":[{"id":11502,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media_gallery\/2351\/revisions\/11502"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media\/2352"}],"wp:attachment":[{"href":"https:\/\/touchimmunology.com\/wp-json\/wp\/v2\/media?parent=2351"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}